濮阳东方价格标准濮阳东方看妇科非常的专业,濮阳东方医院男科治疗阳痿非常靠谱,濮阳东方医院看妇科病评价非常高,濮阳东方妇科医院具体位置,濮阳东方看妇科口碑很高,濮阳东方医院男科治阳痿非常靠谱,濮阳东方医院男科割包皮手术很权威

LOS ANGELES, June 10 (Xinhua) -- The Aquarius/SAC-D observatory, NASA's first ever satellite to study the saltiness of Earth's oceans, is in excellent health after its launch early Friday, initial telemetry reports showed.The observatory rocketed into space from Vandenberg Air Force Base in California atop a United Launch Alliance Delta II rocket at 7:20:13 a.m. PDT (10:20:13 a.m. EDT).Less than 57 minutes later, the observatory separated from the rocket's second stage and began activation procedures, establishing communications with ground controllers and unfurling its solar arrays, NASA's Jet Propulsion Laboratory (JPL) said.During the next 25 days, the Aquarius/SAC-D service platform will be tested and maneuvered into its final operational, near-polar orbit 408 miles (657 kilometers) above Earth. Science operations will begin after the observatory's instruments are checked out. This commissioning phase may last up to 65 days, JPL said.Aquarius will map the global open ocean once every seven days for at least three years with a resolution of 93 miles (150 kilometers). The maps will show how ocean surface salinity changes each month, season and year. Scientists expect to release preliminary salinity maps later this year."Aquarius is a critical component of our Earth sciences work, and part of the next generation of space-based instruments that will take our knowledge of our home planet to new heights," said NASA Deputy Administrator Lori Garver. "The innovative scientists and engineers who contributed to this mission are part of the talented team that will help America win the future and make a positive impact across the globe."Aquarius will measure salinity by sensing thermal microwave emissions from the water's surface with three microwave instruments called radiometers. When other environmental factors are equal, these emissions indicate the saltiness of surface water. A microwave radar scatterometer instrument will measure ocean waves that affect the precision of the salinity measurement.Because salinity levels in the open ocean vary by only about five parts per thousand, Aquarius will be able to detect changes as small as approximately two parts per 10,000, equivalent to about one-eighth of a teaspoon of salt in a gallon of water."Data from this mission will advance our understanding of the ocean and prediction of the global water cycle," said Michael Freilich, director of NASA's Earth Science Division in the Science Mission Directorate at agency headquarters in Washington. "This mission demonstrates the power of international collaboration and accurate spaceborne measurements for science and societal benefit. This would not be possible without the sustained cooperation of NASA, CONAE and our other partners."The Aquarius/SAC-D (Satellite de Aplicaciones Cientificas) observatory is a collaboration between NASA and Argentina's space agency, Comision Nacional de Actividades Espaciales (CONAE).Aquarius was built by NASA's JPL and the Goddard Space Flight Center in Greenbelt, Maryland. NASA's Launch Services Program at the Kennedy Space Center in Florida manages the launch.JPL will manage Aquarius through its commissioning phase and archive mission data. Goddard will manage Aquarius mission operations and process science data. CONAE is providing the SAC-D spacecraft, optical camera, thermal camera with Canada, microwave radiometer, sensors from various Argentine institutions and the mission operations center. France and Italy also are contributing instruments.

SAN FRANCISCO, June 23 (Xinhua) -- Facebook announced Thursday that Netflix CEO and Chairman Reed Hastings has joined the social network company's board of directors.Hastings, who successfully managed Netflix through an IPO in 2002, is expected to provide useful guidance for Facebook which plans to go public.As the most popular subscription-based movie and television show rental service in the United States, Netflix could also help Facebook figure out how to enter the business of music streaming and movies, which, CEO Mark Zuckerberg said at the eG8 Forum held in Paris last month, would be Facebook's next focus.The Facebook board seat could also help Netflix to catch up with the social evolution of the Internet with its 23.6 million subscribers in the U.S. and Canada."Reed is an entrepreneur and technologist who has led Netflix to transform the way people watch movies and TV," said Zuckerberg in a statement. "He has built a culture of continuous rapid innovation, something we share and work hard to build every day.""Facebook is propelling a fundamental change in how people connect with each other and share all kinds of content," said Hastings. "I'm looking forward to working with Mark and the rest of the board to help Facebook take advantage of all the opportunities ahead."

CAIRO, July 6 (Xinhua) -- Egypt's Central Administration of Agricultural Quarantine has denied again that the country's fenugreek seeds exported to Europe caused the E.coli infections which have claimed dozens of lives.The Egyptian authorities took and analyzed fenugreek seeds samples from the warehouse of the said Egyptian exporter and all results were negative by the strain, a statement posted on the official website of Egypt's Agricultural Ministry said on Wednesday."E.coli strain has not been reported in Egypt and no illness cases have been found," it added.If fenugreek seeds sprouts are suspected to be contaminated with E.coli pathogenic strain, it could be related to different handling processes, such as the re-packing or water used for sprouting, the statement said.The European Union (EU) on Tuesday agreed to ban the import of certain types of seeds from Egypt as Egyptian fenugreek seeds were reported to be linked with the outbreak of E.coli in Europe.The European Food Safety Authority (EFSA) published early Tuesday a report from its task force on the E.coli outbreaks in Germany and France, indicating that fenugreek seeds imported from Egypt is the most likely source of the outbreaks.The E.coli outbreak has killed over 50 people in Europe since it was first reported in late May.Russia's food safety watchdog Rospotrebnadzor has also banned the import of certain types of produce from Egypt over food safety concerns, a Russian official said on Wednesday.Egypt's Ministry of Agriculture refuted the claims of Egypt being the source of E.coli Friday.

WASHINGTON, Aug. 16 (Xinhua) -- The White House announced Tuesday that the U.S. Departments of Agriculture, Energy and Navy will invest up to 510 million U.S. dollars in partnership with the private sector to facilitate the country's biofuel industry development."Biofuels are an important part of reducing America's dependence on foreign oil and creating jobs here at home," U.S. President Barack Obama said in a White House statement.The initiative is a response to a directive from Obama issued in March as part of the Blueprint for A Secure Energy Future, the administration's framework for reducing dependence on foreign oil."But supporting biofuels cannot be the role of government alone. That's why we're partnering with the private sector to speed development of next-generation biofuels that will help us continue to take steps towards energy independence and strengthen communities across our country," Obama added.The joint plan calls for the three departments to invest up to 510 million dollars in the next three years, which will require substantial cost share from private industry, in a bid to reduce U. S. reliance on foreign oil and create jobs at home."By building a national biofuels industry, we are creating construction jobs, refinery jobs and economic opportunity in rural communities throughout the country," said U.S. Agriculture Secretary Tom Vilsack.White House figures revealed that the world's largest economy spends more than 300 billion dollars on imported crude oil every year.With a slackening economic recovery and the government's approval rate at a record low level, the Obama administration is rolling out a string of measures in recent days to accelerate economic growth and job creation.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.